| Company Name: | Abiomed, Incorporated | | Ticker Symbol: | ABMD | | | WWW Address: | www.abiomed.com | | CEO: | Michael R. Minogue | | No. of Employees: | 386 | | Common Issue Type: | CS | | Business Description: | The Company is a provider of medical devices in circulatory support and it offers a continuum of care in heart recovery to heart failure patients.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 8.14 |  -0.41 | 7.41 | 8.28 | 8.51 | 8.69 | 8.11 | 220960 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 305.3 | 37.5 | 1.07 | -0.91 | 0.00 | 0.0 | 0.0 | 17.35 - 4.67 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 8.14 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 305.1 | mil |
| Latest Shares Outstanding | 37.5 | mil |
| Earnings pS (EPS) | -0.91 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 189,663 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 36.7 | mil |
| Float as % of Shares Outstanding | 98.1 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 76.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 32.70 | % |
| Gross Profit Margin | 77.9 | % |
| EBITDA Margin | -31.3 | % |
| Pre-Tax Profit Margin | -40.1 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | -23.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -27.7 | % |
| Current Ratio | 5.0 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.73 | $ |
| Cash pS | 0.07 | $ |
| Book-Value pS | 3.04 | $ |
| Tangible Book-Value pS | 1.86 | $ |
| Cash Flow pS | -0.71 | $ |
| Free Cash Flow pS | -0.42 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.68 | |
| Price/Tangible Book Ratio | 4.39 | |
| Price/Cash Flow | -11.5 | |
| Price/Free Cash Flow | -19.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -8.4 | 92 | 2,499 | 7,363 |
| 4 Weeks | 10.36 | 8.11 | 10.16 | -19.9 | 79 | 2,746 | 54,918 |
| 13 Weeks | 11.25 | 7.51 | 8.15 | -0.1 | 94 | 2,503 | 160,191 |
| 26 Weeks | 11.25 | 5.49 | 5.55 | 46.7 | 119 | 2,710 | 344,177 |
| 52 Weeks | 17.35 | 4.67 | 11.83 | -31.2 | 50 | 3,171 | 795,881 |
| YTD | 16.74 | 4.67 | - | -50.4 | 41 | 3,225 | 725,619 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 8.77 | 8.97 | 9.62 | 8.20 | 7.65 | 1.07 | 0.93 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 16.20 | 98.9 | 14.91 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 53.99 | NA | -7.38 |
| R&D | 10.61 | NA | -0.86 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 9.8 | 0.1 | 24.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.04 | -0.03 | 0.35 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 52.16 |
| Current Ratio | 5.0 |
| Quick Ratio (Acid Test) | 4.1 |
| Liquidity Ratio (Cash) | 3.25 |
| Receivables Turnover | 4.9 |
| Average Collection Period | 73 |
| Working Capital/Equity | 61.1 |
| Working Capital pS | 1.90 |
| Cash-Flow pS | -0.71 |
| Free Cash-Flow pS | -0.59 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 9.22 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 14.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 2.1 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 19.35 |
| Tobin's Q Ratio | 2.24 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -10.93 |
| Enterprise Value (EV)/Free Cash Flow | -14.56 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.39 |
| Price/Book Ratio - LTM | 2.68 |
| Price/Cash Flow Ratio | -11.5 |
| Price/Free Cash Flow Ratio - LTM | -19.5 |
| Price/Sales Ratio | 3.97 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.47 |
| Tangible Book Value pS - LTM | 1.86 |
| Book Value pS - LTM | 3.04 |
| Capital Invested pS | 3.09 |
| Cash pS - LTM | 0.07 |
| Cash Flow pS - LTM | -0.71 |
| Free Cash Flow pS - LTM | -0.42 |
| Earnings pS (EPS) | -0.91 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -30.13 |
| Free Cash Flow Margin 5YEAR AVG | -35.83 |
| Net Profit Margin | -43.2 |
| Net Profit Margin - 5YEAR AVRG. | -49.9 |
| Equity Productivity | 0.63 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.63 |
| Return on Capital Invested (ROCI) | -27.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -28.9 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | -23.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | -25.0 |
| Gross Profit Margin | 77.9 |
| Gross Profit Margin - 5YEAR AVRG. | 79.0 |
| EBITDA Margin - LTM | -31.3 |
| EBIT Margin - LTM | -40.1 |
| Pre-Tax Profit Margin | -42.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -49.1 |
| Effective Tax Rate | -2.4 |
| Effective Tax Rate - 5YEAR AVRG. | -1.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 417 |
| Revenue per Employee | 189,663 |
| Net Income per Employee | -81,858 |
| Average Collection Period | 77 |
| Receivables Turnover | 4.9 |
| Day's Inventory Turnover Ratio | 340 |
| Inventory Turnover | 1.1 |
| Inventory/Sales | 20.2 |
| Accounts Payble/Sales | 7.58 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.03 |
| Fixed Assets Turnover | 1.54 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 41.01 |
| Revenue per $ Plant | 9.40 |
| Revenue per $ Common Equity | 0.63 |
| Revenue per $ Capital Invested | 0.63 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 75.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 75.6 |
| Research & Devlopment (R&D) as % of Revenue | 34.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 34.6 |
|
|  
|
| |
 |  |